Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Tigermed Completes $80 Million IPO on the ChiNext Exchange

publication date: Aug 17, 2012
Hangzhou Tigermed Consulting Co., a clinical-stage CRO, staged its IPO today on Shenzhen’s ChiNext exchange. The IPO, which constitutes 25% of the company’s outstanding stock, placed 13.40 million shares in investors’ hands at a price of 37.88 RMB, a price/earnings ratio of 44. The transaction raised 508 million RMB ($80 million) for the company. Tigermed ended its initial trading day at 50 RMB, an increase of 32% for the IPO investors. At that price, the company has a market capitalization of $420 million. More details....

Stock Symbol: (SHE: 300347)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital